Clinical relevance of deferasirox trough levels in β-thalassemia patients

Clinical and Experimental Pharmacology and Physiology

Volumn 45, Issue 2, 2018, Pages 213-216

  Allegra, Sarah ^a   Massano, Davide ^b   De Francia, Silvia ^b   Longo, Filomena ^b   Piccione, Francesca ^b   Pirro, Elisa ^b   Cusato, Jessica ^a   D'Avolio, Antonio ^a   Piga, Antonio ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

creatinine; ferritin; iron overload; therapeutic drug monitoring; thalassemia

Indexed keywords

CREATININE; DEFERASIROX; FERRITIN; IRON; IRON CHELATING AGENT;

ADULT; BETA THALASSEMIA; BODY MASS; CLINICAL ASSESSMENT; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG MONITORING; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; LETTER; LIVER; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; PLASMA; COHORT ANALYSIS; DOSE RESPONSE; IRON OVERLOAD; YOUNG ADULT;

ADULT; BETA-THALASSEMIA; COHORT STUDIES; DEFERASIROX; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; YOUNG ADULT;

EID: 85038254046     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12879     Document Type: Letter

References (25)

1. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up. Blood. 2011;118:884-893.
2. Chauzit E, Bouchet S, Micheau M, et al. A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application. Ther Drug Monit. 2010;32:476-481.
3. De Francia S, Massano D, Piccione FM, et al. A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;893–894:127-133.
4. Cusato J, Allegra S, Massano D, De Francia S, Piga A, D'Avolio A. Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J. 2015;15:263-271.
5. Chirnomas D, Smith AL, Braunstein J, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood. 2009;114:4009-4013.
6. Allegra S, Cusato J, De Francia S, Massano D, Piga A, D'Avolio A. Deferasirox AUC efficacy cutoff and role of pharmacogenetics. Eur J Clin Pharmacol. 2016;72:1155-1157.
7. Cusato J, Allegra S, De Francia S, Massano D, Piga A, D'Avolio A. Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics. 2016;17:561-572.
8. Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood. 2003;101:15-19.
9. Jensen PD. Evaluation of iron overload. Br J Haematol. 2004;124:697-711.
10. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835-847.
11. Kettaneh A, Marcellin P, Douvin C, et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol. 2007;46:628-634.
12. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147:752-759.
13. Piga A, Longo F, Musallam KM, et al. Assessment and management of iron overload in beta-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project. Br J Haematol. 2013;161:872-883.
14. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica. 2006;91:1343-1351.
15. Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873-880.
16. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther. 1999;24:339-346.
17. Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica. 2010;95:557-566.
18. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455-3462.
19. Dhamija M, Mahajan A, Kalra M, Virmani A. Deferasirox in Indian children with thalassemia major: 3 years experience. Indian J Med Paediatr Oncol. 2013;34:16-20.
20. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80:168-176.
21. Aydinok Y, Unal S, Oymak Y, et al. Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naive children with transfusional iron overload. Eur J Haematol. 2012;88:431-438.
22. Cancado R, Melo MR, de Moraes Bastos R, et al. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study. Eur J Haematol. 2015;95:545-550.
23. Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res. 2010;34:864-870.
24. Neukirchen J, Fox F, Kundgen A, et al. Improved survival in MDS patients receiving iron chelation therapy – a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res. 2012;36:1067-1070.
25. Leitch HA, Chan C, Leger CS, Foltz LM, Ramadan KM, Vickars LM. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. Leuk Res. 2012;36:1380-1386.